Synairgen Share Discussion Threads

[quidzinn] 13/11/2009 10:54

39.25 - 7.75 (16.5%) - oops ...

Q

[andrbea] 12/11/2009 13:27

below is the article from RHPS

[adorling] 12/11/2009 12:31

New investors clearly underwhelmed then with the news - trust me to buy in at 58.5p yesterday - must learn to buy on the rumour/results and sell on the news! Another long term hold in the portfolio then.

[andrbea] 12/11/2009 10:46

Isn't the pace of their trials just too slow?

With a proven market for swine flu, copd and asthma, is it prudent to stay independent I wonder? Surely the IFN technology needs to be fast-tracked, either by a full takeover by a major pharma (with the clout to speed up trials, and do them on a larger scale, eg for FSA approval)

... or through franchises of the technology to big pharma

This reminds me of Summit who had promising technology but pursued the independent route and rebuffed suitors who wanted to up stakes or takeover the company.

Any views?


nia dyor

[ayesha4] 12/11/2009 10:45

Except they got the market cap badly wrong.

it is only £30m not £230m

cretins

[investinggarden] 12/11/2009 10:38

Swine flu tests cheer Synairgen

[ayesha4] 12/11/2009 10:29

looks to be a few buyers at this price, worth buying?

the market for asthma is huge

[quraishim] 12/11/2009 09:31

everlastin...definately top slice...and have an holding for the coming weeks...really i bought in early 50...so not much of profit better wait for bigger gains.

[everlastian] 12/11/2009 08:16

Quraishim,

Lets say we end up the day 20% up. Would you cash some profit today or do you believe there is still more potential fo rthe next few weeks/months?

[quraishim] 12/11/2009 07:51

over 60p and now we will wait for 10am for further announcement during conference call interesting times

[quraishim] 12/11/2009 07:20

Synairgen announces successful outcome of Phase I safety and antiviral 'proof of
mechanism' biomarker study of inhaled interferon beta in asthmatic subjects
Southampton, UK - 12 November 2009: Synairgen plc (LSE: SNG), the respiratory
company with a particular focus on viral defence in asthma and chronic
obstructive pulmonary disease ('COPD'), announces the successful outcome of its
second Phase I clinical study (SG004) for inhaled interferon beta ('IFN-beta'),
which the Company is developing for the treatment of viral infection in asthma
and COPD sufferers.

[everlastian] 11/11/2009 17:37

The results of the test of the new drug are positive.
Great annoucement tomorrow.
Target for take over soon...

[quraishim] 11/11/2009 12:55

is it another tree shake???

[quraishim] 11/11/2009 10:42

Well SNG looks certainly on play...mm's to be short and tree shake twice since morning....its looks to cross 60 imo..topped up for blockbuster announcement in coming weeks..... 60p resistance then its all clear for...next movement to its ipo price 120p...(I wish)..........

[cynical sid] 11/11/2009 09:12

Have a look at another IP Group company, Syntopix. Shares are at an all time low. Could be the next big mover...

[andrbea] 11/11/2009 08:43

most importantly, the US patent is already in place (see below)

so we now await clarification (tomorrow hopefully) on the potential of IFN (the yes or no)

"The company, which has won a US patent for IFN Beta since June, expects final results of a second Phase 1 study later this autumn."



nia dyor

[andrbea] 11/11/2009 08:23

Even after the big rise in the share price (after the swine flu rns), the mkt cap is still relatively small IMO.

So got some today.

And having read the excellent iii thread on sng.

Tomorrow (Thursday) there should be a second rns about the copd market:

quote "The experiments were undertaken as part of its development programme for IFN-beta in asthma and chronic obstructive pulmonary disease (COPD)."

the (huge) size of the copd market:



nia dyor

[quraishim] 10/11/2009 08:54

Presentation , conferance call and AGM all this week...bodes well for news on development of its products...Synairgen's 2009 Annual General Meeting ('AGM') will be held at 12 noon on
Wednesday 11 November 2009 at the offices of Fasken Martineau LLP, 17 Hanover
Square, London W1S 1HU. The Notice of the AGM is included in the Annual Report
and Accounts.

[quraishim] 09/11/2009 21:35

part of its development programme for inhaled interferon beta ('IFN-beta') in
asthma and COPD, laboratory experiments have been completed which confirm the
antiviral potency of IFN-beta against 2009 H1N1. The potential is enormous............so is the cost, asthma and swine flu successful antiviral solution can have $billions market...

[littlemadam] 09/11/2009 20:46

Well done you holders. No deramp intended as this sort of share is not my bag, but I suspect it could retrate to 40p for a few weeks and then advance really well. Hang on in there!

[newswseller] 09/11/2009 20:00

In 3-5 years maybe. This is only a Phase II trial, it's a very long way till any product would hit the market and millions more required in clinical research costs. By then swine flu will be a thing of the past.

Jam tomorrow anyone?


quraishim - 9 Nov'09 - 15:31 - 9 of 11


peeps paying 60p earlier on.....the prospects must be enormous...........ukraine has swine flu epidemic......well the demand for these shares might outstrip shares available

[quraishim] 09/11/2009 16:24

mm shaking the tree with no luck of getting loose shares...tomorrow will be interesting due to firm end of day....
Synairgen will be announcing the safety and biomarker results of SG004 on 12
November 2009.Floated five years ago at 130p

[quraishim] 09/11/2009 15:31

peeps paying 60p earlier on.....the prospects must be enormous...........ukraine has swine flu epidemic......well the demand for these shares might outstrip shares available